[go: up one dir, main page]

EG24194A - 5ht-a-partial agonist pharmaceutical compositions - Google Patents

5ht-a-partial agonist pharmaceutical compositions

Info

Publication number
EG24194A
EG24194A EG2002121358A EG2002121358A EG24194A EG 24194 A EG24194 A EG 24194A EG 2002121358 A EG2002121358 A EG 2002121358A EG 2002121358 A EG2002121358 A EG 2002121358A EG 24194 A EG24194 A EG 24194A
Authority
EG
Egypt
Prior art keywords
pharmaceutical compositions
partial agonist
agonist pharmaceutical
partial
compositions
Prior art date
Application number
EG2002121358A
Other languages
English (en)
Inventor
Aubert Jerome
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of EG24194A publication Critical patent/EG24194A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EG2002121358A 2001-12-21 2002-12-17 5ht-a-partial agonist pharmaceutical compositions EG24194A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod

Publications (1)

Publication Number Publication Date
EG24194A true EG24194A (en) 2008-10-14

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2002121358A EG24194A (en) 2001-12-21 2002-12-17 5ht-a-partial agonist pharmaceutical compositions

Country Status (31)

Country Link
US (2) US20050106236A1 (xx)
EP (2) EP1321142A1 (xx)
JP (1) JP4718776B2 (xx)
KR (1) KR100980144B1 (xx)
CN (1) CN100464749C (xx)
AR (1) AR037937A1 (xx)
AT (1) ATE320807T1 (xx)
AU (1) AU2002361198B2 (xx)
BR (1) BR0215148A (xx)
CA (1) CA2470668C (xx)
CO (1) CO5640102A2 (xx)
CY (1) CY1105559T1 (xx)
DE (1) DE60210139T2 (xx)
DK (1) DK1458377T3 (xx)
EC (1) ECSP105163A (xx)
EG (1) EG24194A (xx)
ES (1) ES2258171T3 (xx)
HU (1) HU226589B1 (xx)
IL (2) IL162451A0 (xx)
MX (1) MXPA04006157A (xx)
MY (1) MY139546A (xx)
NO (1) NO20042779L (xx)
NZ (1) NZ533585A (xx)
PE (1) PE20030872A1 (xx)
PL (1) PL369509A1 (xx)
PT (1) PT1458377E (xx)
RU (1) RU2322978C2 (xx)
SI (1) SI1458377T1 (xx)
TW (1) TWI260221B (xx)
WO (1) WO2003053432A1 (xx)
ZA (1) ZA200404467B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1165293C (zh) * 1998-08-21 2004-09-08 诺瓦提斯公司 5ht4激动剂或拮抗剂的新型口服制剂
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE365174T1 (de) 2003-01-28 2007-07-15 Microbia Inc Zusammensetzungen zur behandlung von gastrointestinalen störungen
AU2003222439A1 (en) * 2003-03-25 2004-10-18 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
EP1629280A2 (en) * 2003-05-21 2006-03-01 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
AR045081A1 (es) * 2003-07-24 2005-10-12 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
TWI344363B (en) 2003-09-12 2011-07-01 Amgen Inc Rapid dissolution formulation of a calcium receptor-active compound
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
KR101683318B1 (ko) 2008-12-31 2016-12-07 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 nhe-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
RU2675364C2 (ru) 2013-04-12 2018-12-19 Арделикс, Инк Nhe3-связывающие соединения и способы ингибирования транспорта фосфатов
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
CN118221656A (zh) 2017-01-09 2024-06-21 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd 1−アザビシクロ[3.3.0]オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
CN1165293C (zh) * 1998-08-21 2004-09-08 诺瓦提斯公司 5ht4激动剂或拮抗剂的新型口服制剂
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
EP1200091B1 (en) * 1999-08-03 2008-07-02 Lilly Icos LLC Pharmaceutical composition comprising tadalafil

Also Published As

Publication number Publication date
CN1606438A (zh) 2005-04-13
AU2002361198A1 (en) 2003-07-09
EP1458377B1 (en) 2006-03-22
ES2258171T3 (es) 2006-08-16
EP1321142A1 (en) 2003-06-25
NO20042779L (no) 2004-09-17
DE60210139T2 (de) 2006-08-17
HUP0402492A2 (hu) 2005-07-28
PL369509A1 (en) 2005-04-18
US20090104263A1 (en) 2009-04-23
IL162451A0 (en) 2005-11-20
ZA200404467B (en) 2006-05-31
NZ533585A (en) 2006-04-28
HUP0402492A3 (en) 2008-04-28
KR20040066922A (ko) 2004-07-27
CO5640102A2 (es) 2006-05-31
SI1458377T1 (sl) 2006-08-31
PE20030872A1 (es) 2003-11-24
US20050106236A1 (en) 2005-05-19
ECSP105163A (es) 2010-07-30
CA2470668C (en) 2011-07-05
AU2002361198B2 (en) 2006-06-08
MY139546A (en) 2009-10-30
DE60210139D1 (de) 2006-05-11
ATE320807T1 (de) 2006-04-15
EP1458377A1 (en) 2004-09-22
CN100464749C (zh) 2009-03-04
CA2470668A1 (en) 2003-07-03
PT1458377E (pt) 2006-07-31
JP4718776B2 (ja) 2011-07-06
AR037937A1 (es) 2004-12-22
RU2322978C2 (ru) 2008-04-27
DK1458377T3 (da) 2006-06-12
IL162451A (en) 2009-02-11
BR0215148A (pt) 2004-10-19
TW200410684A (en) 2004-07-01
WO2003053432A1 (en) 2003-07-03
RU2004122631A (ru) 2005-08-10
JP2005516946A (ja) 2005-06-09
MXPA04006157A (es) 2004-10-27
KR100980144B1 (ko) 2010-09-03
TWI260221B (en) 2006-08-21
CY1105559T1 (el) 2010-07-28
HU226589B1 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
EP1450824A4 (en) PHARMACEUTICAL COMPOSITION
HK1072200A1 (en) Pro-micelle pharmaceutical compositions
GB0111597D0 (en) Pharmaceutical compositions
GB2389530B (en) Pharmaceutical compositions
EP1407785A4 (en) MEDICAL COMPOSITIONS
GB2391473B (en) Pharmaceutical compositions
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
EP1408896A4 (en) PHARMACEUTICAL COMPOSITION
GB0129117D0 (en) Pharmaceutical composition
GB0116107D0 (en) Pharmaceutical composition
GB0213481D0 (en) Pharmaceutical compositions
GB0104752D0 (en) Pharmaceutical compositions
GB0127805D0 (en) Pharmaceutical composition
PL370037A1 (en) Pharmaceutical composition
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
GB2382302B (en) Pharmaceutical compositions
IL157411A0 (en) Pharmaceutical composition
PL370907A1 (en) Pharmaceutical compositions
GB0126732D0 (en) Pharmaceutical compositions
GB0125061D0 (en) Pharmaceutical composition
HU0103049D0 (en) Pharmaceutical composition
GB0101743D0 (en) pharmaceutical compositions
GB0121826D0 (en) Pharmaceutical compositions